Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDEPENDENCE: phase 3 study of luspatercept versus placebo in transfusion-dependent myelofibrosis on JAK2 inhibitor therapy
CTR20212346Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Apr 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of luspatercept in myelofibrosis (MF), primary myelofibrosis (PMF), sponsored by Celgene Corporation. Started Apr 2022; status: active.
02
Drugs
luspatercept
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)
Beyond the preview
Go deeper on CTR20212346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212346.